- Home
- TLSA vs MNOV Comparison
TLSA vs MNOV Comparison
Compare TLSA & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- MNOV
- Stock Information
- Founded
- TLSA 2013
- MNOV 2000
- Country
- TLSA United Kingdom
- MNOV United States
- Employees
- TLSA N/A
- MNOV N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- MNOV Health Care
- Exchange
- TLSA Nasdaq
- MNOV Nasdaq
- Market Cap
- TLSA 87.8M
- MNOV 91.7M
- IPO Year
- TLSA 2000
- MNOV 2005
- Fundamental
- Price
- TLSA $0.69
- MNOV $1.83
- Analyst Decision
- TLSA
- MNOV Strong Buy
- Analyst Count
- TLSA 0
- MNOV 1
- Target Price
- TLSA N/A
- MNOV $9.00
- AVG Volume (30 Days)
- TLSA 1.1M
- MNOV 19.7K
- Earning Date
- TLSA 02-18-2025
- MNOV 02-18-2025
- Dividend Yield
- TLSA N/A
- MNOV N/A
- EPS Growth
- TLSA N/A
- MNOV N/A
- EPS
- TLSA N/A
- MNOV N/A
- Revenue
- TLSA N/A
- MNOV N/A
- Revenue This Year
- TLSA N/A
- MNOV N/A
- Revenue Next Year
- TLSA N/A
- MNOV N/A
- P/E Ratio
- TLSA N/A
- MNOV N/A
- Revenue Growth
- TLSA N/A
- MNOV N/A
- 52 Week Low
- TLSA $0.41
- MNOV $1.12
- 52 Week High
- TLSA $1.74
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- TLSA 44.46
- MNOV 37.74
- Support Level
- TLSA $0.65
- MNOV $1.83
- Resistance Level
- TLSA $0.70
- MNOV $1.88
- Average True Range (ATR)
- TLSA 0.05
- MNOV 0.07
- MACD
- TLSA 0.00
- MNOV -0.01
- Stochastic Oscillator
- TLSA 22.00
- MNOV 0.75
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.